Ensuring Compliance with Marketing, Advertising and Promotional Requirements for Pharmaceuticals and Medical Devices 2017 : Two Day Seminar

By: David R Dills, Regulatory Affairs & Compliance Consultant.
Product code: SEM23
Location 1: San Diego CA Sep 14 - 15

Description

An Interative Workshop Presented BY David R. Dills -Global Regulatory Affairs & Compliance Consultant 

Course “Regulatory & Compliance Strategies: Marketing, Advertising and Promotion of Pharmaceuticals and Medical Devices“ has been pre-approved by RAPS as eligible for up to 12 credits towards a participant's RAC recertification upon full completion.

Each attendee will receive 2-Day workshop materials by the speaker. Seminar Also Includes Certificate, 
Complimentary Breakfast, Lunch & High Tea/Coffee provided by WCS

The changing game for drug and device marketing, however, is governed by antiquated and inadequate rules created for traditional print and broadcast advertising by the Food and Drug Administration (“FDA”). How the FDA will deal with such advanced communication technology that can go “viral” and just as quickly disappear is the question that the industry is eager to have answered.

The FDA regulates the promotion of prescription drugs, biologics, medical devices and biotechnology products to ensure that the information is not false or misleading. The FDA has for decades regulated traditional advertising for decades, published various guidance documents for industry and issued many violation letters. If the FDA determines that drug or medical device promotional material is false or misleading or lacking in fair balance as between benefits and risks, companies could be forced to implement costly corrective actions, such as remedial advertising, suffer damage to their reputations and incur monetary fines. Already, the government has collected billions of dollars in fines, forfeitures and disgorgements from drug companies for the alleged marketing of a product for unapproved, or “off-label,” uses.

In the worst case, responsible executives can be criminally prosecuted for such violations under a strict liability standard, meaning that the government is not required to show that the executive had any intent to violate FDA regulations or had any knowledge of such violations. In addition, Social Media is used by healthcare professionals, sales representatives and consumers to discuss the use of prescription products for specific diseases and conditions. The use of Social Media tools and potential concerns will be addressed.

Rx drug promotion is delivered to two distinct audiences: health care professionals (HCPs) and consumers. Although tasked with regulatory oversight, FDA recognizes that promotional efforts can provide HCPs as well as consumers important information about the newest developments in drug therapies. The value of such information depends upon the integrity and completeness of the information being presented.

FDA regulates all Rx drug “promotional materials,” which includes both labeling and advertisements. Examples of “labeling” include, but are not limited to, brochures, booklets, detailing pieces, bulletins, calendars, motion pictures and slides. Advertisements include, but are not limited to, materials published in journals, magazines, other periodicals, and newspapers, and advertisements broadcast through media such as radio, television and telephone communications systems. Rx drug advertising to doctors, known as “detailing,” occurs in a variety of settings. In addition to medical offices, detailing occurs in hospitals, pharmacies, at medical meetings and symposia, academic settings, conferences and other meeting facilities. The FDA also regulates direct-to-consumer (DTC) Rx drug advertising. While FDA has complete jurisdiction over prescription drug labeling and advertising, as well as all medical device labeling, it has limited jurisdiction over medical device advertising.

Areas Covered

Gain a better understanding of how the regulatory and legal environment has evolved and affects the marketing and promotion of pharmaceuticals and medical devices

Receive practical, day-to-day guidance based from the latest FDA enforcement actions, and the changes taking place and being contemplated

Get a first-hand update on the status of social media guidance documents

Identify the trends reflected in the latest enforcement actions and policies issued by the FDA

---  Discuss the policies and actions being taken by OIG and DOJ under the False Claims Act and other Acts

---- Summarize regulations, enforcement actions, guidelines and trends affecting the advertising and promotion of medical devices and drugs

--- Identify key regulatory issues surrounding complex and rapidly shifting hot topics in advertising and promotion

---  Conduct risk assessments for products and promotional strategies

--  Reviews

Who will Benefit

This seminar will provide an overview and in-depth snapshot of the key principles and requirements for advertising and promotion expectations and ensuring compliance success. This seminar will assist personnel who have varying levels of experience in drug and device advertising, marketing and promotion. It is intended for those involved with Regulatory Affairs, Marketing and promotional legal issues, Marketing, sales and support functions but could benefit other personnel. Employees who will benefit include all levels of management and departmental representatives from key functional areas and those who desire a better understanding or a "refresh" overview of the advertising and promotional requirements for drugs and medical devices, including:

  • Management responsible for regulatory and GMP/GLP/GCP compliance and other regulatory requirements seeking a better understanding of FDA, advertising and promotional requirements, regulatory actions and how they can i

    Learning Objectives

    Advertising and promotion of drugs and medical devices is a significant post-market activity of the FDA regulated industry. While maintaining a competitive marketing strategy is increasingly important in today’s marketplace, it is also critical to remain in compliance with FDA statutes and regulations regarding advertising and promotion of drugs and medical products. Disregarding these principles and requirements can result in FDA enforcement actions, including receiving a Warning Lette

Course Outline:

Day 1 Schedule

  • Introductions and Background
  • Advertising and Promotion Regulation Overview
  • Required Elements of All Advertising and Promotional Materials for Drugs and Medical Devices
  • Laws Governing Advertising and Promotion: FDA
  • Lawful Pre-FDA Approval & Pre-FDA Clearance Communication
  • Promotion, Labeling and Advertising
  • Misbranding/Off-Label Information and Issues
  • In-Depth Analysis of Requirements for Advertising and Promotion
  • FDA Enforcement Surveillance
  • Social Media, Latest FDA Trends and Advertising and Promotion issues related to Social Media
  • A structure for analysis of responsibility for promotion in social media.
  • Recent FDA enforcement situations involving social media.
  • What must product claim ads tell you?
  • What are ads not required to tell you?
  • Does the law say anything about the design of ads for prescription drugs?
  • Has FDA done research on DTC advertising?
  • How can an ad violate the law?
  • Who should I tell if I think that a prescription drug ad violates the law?
  • What does FDA do if it determines that an ad violates the law?
  • What is Off-Label and the consequences with HCP’s?
  • Off-Label Promotion Tactics and Off-Label Promotion of Medical Devices: Maximizing Your Performance Claims within FDA's Framework of Acceptable Practices
  • Medical Education
  • Why FDA has complete jurisdiction over prescription drug labeling and advertising, as well as all medical device labeling, but has limited jurisdiction over medical device advertising?
  • FDA and FTC Enforcement
  • The FDA has an escalating arsenal of enforcement tools from informal notices to formal administrative notices to civil actions and finally to criminal prosecution.

 

Day 2 Schedule

  • Untitled Letter and the Warning Letters
  • Seizures
  • Injunctions/Consent Decrees
  • OIG/DOJ/False Claims Act and Other Acts and OIG Settlements/CIA’s
  • Physician Payments Sunshine Act
  • The federal Anti-Kickback statute presents many potential pitfalls for medical device manufacturers looking to promote their products.
  • Disclose risk information in prescription drug and medical device promotion appropriately and effectively to healthcare professionals and consumers
  • Company Policies and Procedures
  • AdvaMed Code of Ethics on Interactions with HCP’s
  • Integrating FDA compliance elements into Healthcare Compliance or Corporate Compliance programs and overview of the standards with HHS-OIG Guidance
  • Recent Trends and Enforcement Actions

Recap of Day 1 and Day 2

Exercise on Day 2

  • Interactive Discussions
  • Review Regulatory and Compliance Documentation
  • Recent Enforcement Actions

Debrief/Adjourn/Wrap-Up

 

speaker

David R DillsRegulatory Affairs & Compliance Consultant

David R. Dills,Global Regulatory Affairs & Compliance Consultant currently provides regulatory affairs and compliance consultative services for early-stage and established Class I/II/III device, IVD, biopharmaceutical, cosmetics and nutraceutical manufacturers on the global landscape, and has an accomplished record with more than 27 years of experience in the areas of Regulatory Affairs, Compliance and Quality Systems. He has been previously employed, with increasing responsibilities by device manufacturers and consultancies, including a globally recognized CRO and has worked directly with manufacturers engaged in compliance remediation activities involving consent decrees, CIA’s, warning letters, and customer generated compliance events, conducts QS, regulatory, compliance assessments/audits and FDA Mock Inspections for State of Readiness. 

He has been directly involved with constructing, reviewing, and remediating regulatory submissions, U.S. Agent for OUS companies, works closely with the key stakeholders and Agency/Center Reviewers regarding submission meetings and negotiations; clinical affairs/CTM and provides regulatory submissions and post-market project leadership and guidance covering multiple therapeutic and medical specialties based on classification. He has a strong background in the interpretation and applicability of FDA and international regulations, leads activities for the registration and approval process and working with the Agencies in Asia Pacific, EMEA and The Americas, including FDA, European Medicines Agency–EMA, MHRH, ANVISA, PMDA, MOH, CFDA, TGA, and Health Canada and works with management on regulatory strategies and plans supporting a company’s commercialization strategy. He directs and leads efforts for PM support involving all phases of the premarketing to postmarketing; establishes Medical Device Single Audit (MDSAP), UDI, and Digital Marketing/Promotion/Advertising compliance strategies; lead efforts regarding AE/Incident Reporting, all aspects of Postmarketing Surveillance and Vigilance Reporting; establish QMS and documentation systems for GxP compliance; ISO 13485 registration and CE Mark, Technical File, Design Dossier and CER consultation; and facilitates multi-country product registrations and licensing. 

He recommends action to senior leadership to ensure effective resolution for manufacturers to achieve sustainable and proven compliant systems. Background encompasses broad capabilities in quality systems; documentation development and remediation; regulatory oversight and governance; design controls; CAPA investigations; GxP training; software embedded medical devices/all aspects of SW/SDLC and process validation with compliance oversight; supplier management; and demonstrates credible experience to optimize business performance through proactive strategies to mitigate compliance exposure. Mr. Dills has served on the Faculty Advisory Board for the Pharmaceutical Training Institute, Editorial Advisory Boards for Software Quality Professional and the Institute of Validation Technology (IVT), publisher of the Journal of GXP Compliance and Journal of Validation Technology and on the Readers’ Board for Medical Device & Diagnostic Industry and Medical Product Manufacturing News and was nominated and accepted for inclusion into the 2005-2006 Strathmore’s Who’s Who of Professionals. 

Mr. Dills has authored and published validation, regulatory and compliance-related articles, commentaries and technical guides, and is an accomplished global industry presenter. Mr. Dills’ academic degrees include Environmental Science and Biology. He is a former Chair and Co- Chair of ASQ’s Section 1506 and affiliated with the Biomedical Division, RAPS, AdvaMed, PDA, ISPE, and other industry working group

14-September-2017 To 15-September-2017 San Diego CA
Seminar One Registration
$ 1049



Special Group Discount Register for Four attendees
$ 3896

Please call any of our customer support on 844-267-7299 to avail the below discount for your Group

2 Attendees - 2% off

3 to 6 Attendees - 5% off

7 to 10 Attendees - 7% off

10+ Attendees - 15% 0ff

Other Modes of Payment

Want to register by Wire Transfer?
Please call any of our customer support on 844-267-7299 to help you completed the transfer.

Want to register by check or PO?
Please call any of our customer support on 844-267-7299 or drop any email to help you completed the purchase.

Download Registration Form

Yes, I want to attend this Seminar

Click here to Download Registration Form

Hilton Garden Inn San Diego / Del Mar     
11025 Vista Sorrento Parkway | San Diego, CA | 92130 
Phone: +1 858-720-9500

How to Reach

Testimonials

I have attended various seminars from WCS but this "Live" one was incredible. This seminar was excellent.

Pfizer Quality Manager

I liked WCS training style. WCS speakers gave excellent examples to back up what speaker was explaining. Which helped me grasp a better understanding."

RA/QA Manager Abbott

The presenter was excellent session leader, very knowledgeable and well-spoken. The topic was well chosen and interaction between the participants and the presenter was good.

Chief Compliance Officer
 

This was an informative seminar. Provided very valuable insight into how the FDA works. Presenters' experience in real life events and interaction with the FDA is priceless.

Quality Assurance Medtronic

“I enjoyed the training, the instructor was engaging and were able to modify the course to make it more applicable for small group.”

Peter Belsito, Director of Quality TSI

Awesome material covered.  Andbero Magleo, IT Admin Passy-Muir

“Very informative with enough details to start putting together action plans. Susan Murphy, Associate Director, Quality investigation (QA) LFB USA

“I learned a lot from the instructor and trainee good.” David QU, senior Analytical Chemist Dalton Pharma Services.

 

“Well placed, a lot of good information. Good interaction between participants. Held at a good location. More was US based examples given.” Nicola Mootoo, Senior Validation Engineer Shire Pharmaceuticals

 

“Well delivered seminars, right place, good contents.” Evelyn Chang, Corporate manager Genzyme.


“I though the contents of the presentation and the discussion was very good.”Mary Beird, Regulatory Compliance Manager Charles River laboratories International, Inc.

 

“Great session. I learned a lot” Chief HR Professional"

“Wow!  I had an opportunity to attend the HR audit workshop.  It is spectacular and I found it very valuable.
It will help us audit and manage strategic HR issues.” The president of a major insurance and risk management agency.

“I found the audit session very useful; it will help us identify and manage key HR management issues.” A senior auditor

“The session provided important information about HR auditing. It will help us audit critical HR issues and outcomes
 and will help us assess the organization’s culture and values.” A Chief Internal Auditor

“I’ve been doing a lot of research lately on HR audits, trying to find the best system for us.
This session and ELLA seems to really fit the bill for us.” A human resource manager

 

Media Partners

Top Media Partners and Sponsors World Compliance Seminars WCS


speaker

Morf Media, Inc. is shaping the future of enterprise compliance training for the mobile workforce. For the first time, a digital compliance training system, Morf Learning™, provides one to one training to millions on a smart phone or tablet. Now in pilot with more than 100 major companies in the financial services and life sciences industries, Morf Learning is proving to be cost-effective and engaging. Morf Learning delivers three-minute mini lessons with a personalized Virtual Coach™ developed using the Octalysis framework designed by world-renowned gamification leader, Yu-Kai Chou. 


speaker

Benefits of enrolling for Media Partner

Your company Logo on all the mailings before and after the event.

Get 10% discount to media partner's subscribers.

Publish your Logo and company data on the event website.

Publish your Logo on the conference material distributed during the conference.

Media Partner’s brochure distributed along with conference material


speaker

MEDIA PARTNERS WORK TO DO

Publish Banner on the Media Partner website.

Insertion of the WCS event in the event calendar, both printed and/or online.

Announcement article of the conference on the Magazine and/or Website.

Dedicated email blast to all subscribers

Sponsors

Top Sponsors for WCS - World Compliance Seminars


speaker

If you wish to sponsor our event

Please contact us: 

partner@worldcomplianceseminars.com or speak with one of the account manager + 844 267-7299


speaker

$2,000 - Silver Sponsor Package Includes

Company name and logo on all materials related to events, and prominent location on WCS web site and event media releases 

Listing in monthly Community Leader newsletter sent to over 50,000 users. 

1 Free Pass for the 2 Day Workshop

Sponsors materials will be distributed onsite to all the attendees


speaker

$4,000 - Silver Gold Package Includes

Company name and logo on all materials related to events, and prominent location on WCS web site and event media releases 

Listing in monthly Community Leader newsletter sent to over 50,000 users. 

2 Free Pass for the 2 Day Workshop

Sponsors materials will be distributed onsite to all the attendees

15-20 minutes product demo during the live session

San Diego Cabrillo National Monument, San Diego CA

The first European to set foot in California was the Spanish explorer Juan Rodriguez Cabrillo, who stepped on shore near this spot in in 1542. He's the guy they made this statue to look like -

Sea Creatures at Birch Aquarium, San Diego CA

Birch Aquarium is north of San Diego in La Jolla. It's not as big as some of the other aquariums in California or as flashy as the big sea-themed park down the road, but instead just right, fil

Legoland, San Diego CA

Legoland theme park takes its inspiration from Lego toys, those cute little bricks that snap together to build all kinds of fun things. It's one of several Legolands worldwide.

San Diego Zoo Safari Park, San Diego CA

The San Diego Zoo's sister park offers a different kind of animal experience. Its name (Safari Park) is the clue and it indeed offers a more safari-like experience. Lots of large animals live i

Coronado Island, San Diego CA

Coronado isn't really an island but a peninsula - a fact that doesn't get in the way of the name most people use for it. Whatever you call it, it's on a slender strip of land between th

Balboa Park, San Diego CA

Originally built for temporary use during the 1915-16 Panama-California Exposition in San Diego, Balboa Park boasts buildings beautiful enough to be considered attractions in themselves, especially

La Jolla, San Diego CA

In Spanish, La Jolla means "the jewel," an apt name for a pretty, Mediterranean-style seaside town - sitting on cliffs flanking the ocean.
La Jolla visitors like to shop and eat in

Back to Top